State of the Therapeutics landscape in Q3 2025
In this update, we explore the European investment landscape of Therapeutics in Q3 2025.
The quarter saw venture capital normalize. Most capital concentrated on mature assets, skewing capital distribution notably. Consequently, median deal size rose considerably in growth-stage rounds. Oncology remained the most popular field, with an emphasis on modular biologics and computational discovery.
